Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Authors: Darrell White, Gary J. Schiller, Sumit Madan, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane R. Van Domelen, Ohad S. Bentur, Muhamed Baljevic

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: selinexor, once weekly dose, optimal triplet combination, relapsed/refractory multiple myeloma, pomalidomide, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1352281/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/faf3645ed4d642638bc528022e510fa6